Health outcomes and cost-effectiveness of aprepitant in outpatients receiving antiemetic prophylaxis for highly emetogenic chemotherapy in Germany

European Journal of Cancer

Volumn 43, Issue 2, 2007, Pages 299-307

  Lordick, Florian ^a   Ehlken, Birgit ^b   Ihbe Heffinger, Angela ^a   Berger, Karin ^b   Krobot, Karl J ^c   Pellissier, James ^d   Davies, Glenn ^d   Deuson, Robert ^d  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b MERG   (Germany)

^c MSD Sharp and Dohme GmbH   (Germany)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Antiemetic prophylaxis; Aprepitant; Chemotherapy induced nausea and vomiting; Cost effectiveness analysis; Health outcomes

Indexed keywords

APREPITANT; CISPLATIN; DEXAMETHASONE; ONDANSETRON; PLACEBO;

ARTICLE; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE ASSOCIATION; DRUG DOSE REGIMEN; GERMANY; HUMAN; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; OUTCOMES RESEARCH; OUTPATIENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL;

ANTIEMETICS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; CLINICAL TRIALS, PHASE III; COST-BENEFIT ANALYSIS; DEXAMETHASONE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; HEALTH RESOURCES; HUMANS; MORPHOLINES; MULTICENTER STUDIES; NAUSEA; NEOPLASMS; ONDANSETRON; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME; VOMITING;

EID: 33846291078     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2006.09.019     Document Type: Article

References (39)

1. Coates A., Abraham S., Kaye S.B., et al. On the receiving end - patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol 19 (1983) 203-208
2. De Boer-Dennert M., de Wit R., Schmitz P.I., et al. Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists. Br J Cancer 76 (1997) 1055-1061
3. Gralla R.J., Osoba D., Kris M.G., et al. Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. J Clin Oncol 17 (1999) 2971-2994
4. Wilder-Smith O., Borgeat A., Chappuis P., Fathi M., and Forni M. Urinary serotonin metabolite excretion during cisplatin chemotherapy. Cancer 72 (1993) 7
5. Grunberg S.M., Deuson R., Mavros P., et al. Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer 100 (2004) 2262-2267
6. Aapro M.S., Thuerlimann B., Sessa C., de Pree C., Bernhard J., Maibach R., and on behalf of the Swiss Group for Clinical Cancer Research (SAKK). A randomized double-blind trial to compare the clinical efficacy of granisetron with metoclopramide, both combined with dexamethasone in the prophylaxis of chemotherapy induced delayed emesis. Ann Oncol 14 (2003) 291-297
7. Hickok J.T., Roscoe J.A., Morrow G.R., King D.K., Atkins J.N., and Fitch T.R. Nausea and emesis remain significant problems despite prophylaxis with 5-hydroxytryptamine-3 antiemetics. Cancer 97 (2003) 2880-2886
8. Hesketh P.J., Grunberg S.M., Gralla R.J., et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational randomized double-blind, placebo-controlled trial in patients receiving high dosecisplatin-the Aprepitant Protocol 052 Study Group. J Clin Oncol 21 (2003) 4112-4119
9. Poli-Bigelli S., Rodriguez-Pereira J., Carrides A., et al. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Cancer 97 (2003) 3090-3098
10. De Wit R., Herrstedt J., Rapoport B., et al. The oral NK1 antagonist aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomized, placebo-controlled phase III clinical trials. Eur J Cancer 40 (2004) 403-410
11. Grunberg S.M., Boutin N., Ireland A., Miner S., Silveira J., and Ashihaga T. Impact of nausea/ vomiting on quality of life as a visual analogue scale-derived utility score. Support Care Cancer 4 (1996) 435-439
12. Borjeson S., Hursti T.J., Peterson C., et al. Similarities and differences in assessing nausea on a verbal category scale and a visual analogue scale. Cancer Nurs 20 (1997) 260-266
13. Sun C.C., Bodurka D.C., Donato M.L., et al. Patient preferences regarding side effects of chemotherapy for ovarian cancer: Do they change over time. Gynecol Oncol 87 (2002) 118-128
14. Lindley C.M., Hirsch J.D., O'Neill C.V., Transau M.C., Gilbert C.S., and Osterhaus J.T. Quality of life consequences of chemotherapy-induced emesis. Qual Life Res 1 (1992) 331-340
15. Kassenärztliche Vereinigung. Punktwerte, Kassenärztliche Vereinigungen; 2004.
16. Einheitlicher Bewertungsmaßstab (EBM). Köln, Deutscher Ärzte Verlag, Stand 2003.
17. Institut für das Entgeltsystem im Krankenhaus (InEK gGmbH); 2003. http://inek.customer.msim.de/ [October 2003].
18. Rote Liste. Arzneimittelverzeichnis des BPI und VFA. Bundesverband der Pharmazeutischen Industrie e.V. Frankfurt, Aulendorf, Editio Cantor Verlag; 2004.
19. National Comprehensive Cancer Network. NCCN antiemesis practice guidelines. Oncology 11 (1997) 57-89
20. Uyl-de Groot C.A., Wait S., and Buijt I. Economics and health-related quality of life in antiemetic therapy: recommendations for trial design. Euro J Cancer 36 (2000) 1522-1535
21. Brüggenjürgen B., and Du Bois A. Wirksamkeit und Kosten der 5HT3 Antagonisten beim akuten chemotherapieindiziertem Erbrechen. Med Klin 92 12 (1997) 747-752
22. Roila F., and Ballatori E. The efficacy and cost-effectiveness of various antiemetic regimens. Curr Opin Oncol 10 (1998) 310-315
23. Ballatori E., Roila F., Berto P., et al. Cost and cost-effectiveness analysis of ondansetron versus metoclopramide regimens - a hospital perspective from Italy. PharmacoEconomics 5 (1994) 227-237
24. Lachaine J., and Crott R. Cost-effectiveness of antiemetics use during cancer chemotherapy. Expert Rev. Pharmacoeconomics Outcomes Res 3 (2003) 263-272
25. National Institute for Health and Clinical Excellence (NICE). Guide to the methods of technology appraisal. http://www.nice.org.uk/pdf/TAP_Methods.pdf [10.02.2006].
26. Sanchez L.A., Holdsworth M., and Bartel S.B. Stratified administration of serotonin 5HT3 receptor antagonists (setrons) for chemotherapy-induced emesis. Pharmacoeconomics 18 (2000) 533-556
27. Du Bois A. Management der Chemotherapie-induzierten Emesis: Was ist Standrad nach 20 Jahren klinischer Forschung. Med Klin 93 Suppl. 1 (1998) 3-17
28. McCrea J.B., Majumdar A.K., Goldberg M.R., et al. Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone. Clin Pharmacol Ther 74 (2003) 17-24
29. Hesketh P.J. Defining the emetogenicity of cancer therapy regimens: relevance to clinical practice. The Oncologist 4 (1999) 191-196
30. Warr D.G., Grunberg S.M., Gralla R.J., et al. The oral NK1 antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: pooled data from 2 randomized, double blind, placebo controlled trials. Eur J Cancer 41 (2005) 1278-1285
31. Hesketh P.J., Grunberg S.M., Herrstedt J., et al. Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment response. Support Care Cancer 14 (2006) 354-360
32. Ihbe-Heffinger A., Ehlken B., Bernard R., et al. The impact of delayed chemotherapy-induced nausea and vomiting on patients, health resource utilization and costs in German cancer centers. Ann Oncol 15 (2004) 526-536
33. Kris M.G., Hesketh P.J., Herrstedt J., et al. Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy. Support Care Cancer 13 (2005) 85-96
34. MASCC guidelines. www.mascc.org [March 2005].
35. Jakob A., Bokemeyer C., and du Bois A. Antiemetische therapie. Der Onkologe 9 (2003) 482-494
36. Geling O., and Eichler H.G. Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol 23 (2005) 1289-1294
37. Huang J.Q., Zheng G.F., Chan G.C.F., et al. Efficacy of current antiemetic treatments for preventing delayed chemotherapy-induced nausea and vomiting: a meta-analysis of randomized clinical trials. Clin Res Reg Affairs 21 (2004) 191-212
38. Institute of Medical Statistics (IMS). IMS Cancer Patient Audit/Oncology Analyzer 2nd quarter; 2005.
39. In: Drummond M.F., O'Brien B., Stoddart G.L., and Torrance G.W. (Eds). Methods for the economic evaluation of health care programmes. 2nd ed. (1997), Oxford University Press